Evidence map›Paper›PMID 36376790›Full record

ArticleBMC infectious diseases2022

Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients.

Haruki Wakai, Natsumi Abe, Touno Tokuda, Rika Yamanaka, Satoshi Ebihara, Kensuke Izumaru, Daisuke Ishii, Toru Hyodo, Kazunari Yoshida

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Haruki WakaiReiseikai Medical Corporation Shinagawa Garden Clinic, Imasu Ohsaki Building 2F, 1-20-3 Ohsaki, Shinagawa, Tokyo, 141-0032, Japan. harukiwakai@reiseikai.org.
Natsumi AbeReiseikai Medical Corporation Shinagawa Garden Clinic, Imasu Ohsaki Building 2F, 1-20-3 Ohsaki, Shinagawa, Tokyo, 141-0032, Japan.
Touno TokudaReiseikai Medical Corporation Shinagawa Garden Clinic, Imasu Ohsaki Building 2F, 1-20-3 Ohsaki, Shinagawa, Tokyo, 141-0032, Japan.
Rika YamanakaReiseikai Medical Corporation Shinagawa Garden Clinic, Imasu Ohsaki Building 2F, 1-20-3 Ohsaki, Shinagawa, Tokyo, 141-0032, Japan.
Satoshi EbiharaReiseikai Medical Corporation Shinagawa Garden Clinic, Imasu Ohsaki Building 2F, 1-20-3 Ohsaki, Shinagawa, Tokyo, 141-0032, Japan.
Kensuke IzumaruReiseikai Medical Corporation Gotanda Garden Clinic, Kanpai Building 7F, 5-22-27 Higashi-Gotanda, Shinagawa, Tokyo, 141-0022, Japan.
Daisuke IshiiDepartment of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Toru HyodoDepartment of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Kazunari YoshidaDepartment of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Kishokai Medical Corporation · JPKitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere is no report on antibody titers after vaccination against SARS-CoV-2 in Japanese dialysis patients. As dialysis is different between Japan and other countries, changes in antibody titers were examined.

methodsBaseline characteristics and anti-spike protein antibody titers (Roche) over 90 days after administration of the BNT162b2 messenger RNA vaccine were investigated in dialysis patients.

resultsThe maximum anti-spike protein antibody titer after the second dose was 738 (327 to 1143) U/mL and was reached at 19 (17 to 24) days after the second dose. Antibody titers decreased over time, with titers of 770 (316 to 1089) U/mL at 15 days, 385 (203 to 690) U/mL at 30 days, 254 (138 to 423) U/mL at 60 days, and 208 (107 to 375) U/mL at 90 days after the second dose. When an antibody titer of 137 U/mL was assumed to be a measure related to breakthrough infection, the proportion of subjects with antibody titers exceeding this level was 90.1% at 15 days, 85.3% at 30 days, 75.0% at 60 days, and 65.4% at 90 days after the second dose. When a decrease in antibody titers below the assumed breakthrough level was defined as an event, subjects with a pre-dialysis albumin ≥ 3.5 g/dL were significantly less likely to experience an event than subjects with a pre-dialysis albumin < 3.5 g/dL.

conclusionsThe presence of anti-spike protein levels ≥ 313 U/mL at 30 days after the second vaccine dose might be a factor in maintaining enough antibody titers at 90 days after. Whether an additional vaccine dose is needed should be determined based on indicators serving as factors in maintaining antibody titers as well as the status of the spread of infection.

Indexed as

COVID-19VaccinesAlbuminsAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesDialysisHumansJapanmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAlbuminsAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2VaccinesAntibody titerCOVID-19DialysisSARS-CoV-2Vaccine

Identifiers

PMID36376790
PMCPMC9661455
OpenAlexW4309013170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.